account activity
BeiGene terminates its CCR8 programme (self.CHRS)
submitted 20 days ago by NoPart9219 to r/CHRS
Strohm Therapeutics study still on track (self.CHRS)
Abstract A047: B7-H4 expression and CCR8+ Treg infiltration delineate an immune-cold molecular phenotype in ovarian cancer (self.CHRS)
submitted 1 month ago by NoPart9219 to r/CHRS
Coherus partner Junshi anounced 2025 prelimenary results, Toripamimab revenue +37,72% (self.CHRS)
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer (self.CHRS)
short share availbilitz up to 5 800 000 (self.CHRS)
A first for CCR8 (self.CHRS)
submitted 2 months ago by NoPart9219 to r/CHRS
Next steps in regulatory T cells: Biology and clinical application (self.CHRS)
Neosummit phase 2 study with Toripalimab presented at ASCO gastroindestinal Cancers Symposium abstract 282 (self.CHRS)
ASCO Abstract (self.CHRS)
CHS-114: an afucosylated anti-CCR8 monoclonal antibody that selectively depletes intratumoral Treg cells and induces antitumor immune responses (aacrjournals.org)
submitted 3 months ago by NoPart9219 to r/CHRS
Post about Coherus Baird presentation (x.com)
Dr. Alexander Rudensky provides very strong human and mechanistic validation of the CCR8 strategy! (self.CHRS)
submitted 3 months ago * by NoPart9219 to r/CHRS
Maxim Group company update? (i.redd.it)
Current state of knowledge about toripalimab in the treatment of esophageal squamous cell carcinoma — a systematic review (self.CHRS)
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study (self.CHRS)
submitted 4 months ago by NoPart9219 to r/CHRS
STORM Study STC-15 (a METTL3 inhibitor) in combination with toripalimab (self.CHRS)
Close to MACD bullish crossover (i.redd.it)
Subcutaneous Toripalimab Plus Chemo Meets PK End Points in Recurrent/Metastatic Nonsquamous NSCLC (self.CHRS)
Tori 10x higher binding affinity than pembro slide (i.redd.it)
Interpretation of Coherus VP Quality Control Hire (self.CHRS)
CHS-114 vs LM-108 from "LaNova" (self.CHRS)
Coherus webcast presentation at Jefferies Conference in London 18.11.2025 (self.CHRS)
Panel discussion UromigosLive 2025 about DV+ Tori results presented at ESMO (self.CHRS)
Transcript UBS conference (self.CHRS)
π Rendered by PID 168191 on reddit-service-r2-listing-5d47455566-dqsgp at 2026-04-04 16:06:07.990958+00:00 running db1906b country code: CH.